ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1378

Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Abstract Number: 1148

Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)

8:30AM-10:30AM: Abstract Number: 1145

Prevalence of and Risk Factors for Vertebral Fractures and Low Bone Mass Density Among Women Aging with HIV in Peru

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster (1135–1149)

8:30AM-10:30AM: Abstract Number: 1043

Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1010

Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease

Pediatric Rheumatology – Basic Science Poster (1007–1013)

8:30AM-10:30AM: Abstract Number: 1355

Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study

Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

8:30AM-10:30AM: Abstract Number: 1100

Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease: A Case Series of 13 Patients

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1380

Quality of Life in Patients with Scleroderma Associated Calcinosis Cutis: A Cross-Sectional Study

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

8:30AM-10:30AM: Abstract Number: 1266

Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1023

Racial and Ethnic Distribution of Rheumatic Diseases in Health Systems of the National Patient-Centered Clinical Research Network

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1264

Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1034

Racial/ethnic Differences in Lupus Pregnancy Outcomes over 1 Decade: A US National Study

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1243

Real World Validation of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis: Analysis from the RISE Registry

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1283

Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1365

Release of High-Mobility Group Box-1 After an Raynaud’s Attack Potentially Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].